NVAX Share Price Performance
US$10.11
2.24 (28.46%)
26.6% undervalued intrinsic discount
US$13.78
Fair Value
Price US$10.11
AnalystConsensusTarget US$13.78
AnalystLowTarget US$6.00
AnalystHighTarget US$25.00
Fair ValueUS$13.78
Share Pricen/a
Novavax, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 115 Fair Values set on narratives written by author
NVAX Community Narratives
AN
Fair Value US$13.78 26.6% undervalued intrinsic discount
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
0users have liked this narrative
0users have commented on this narrative
54users have followed this narrative
AN
Fair Value US$6 68.5% overvalued intrinsic discount
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$25 59.6% undervalued intrinsic discount
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
Key Takeaways Strategic partnerships and a leaner operating model are expected to boost profitability and enable new high-margin, recurring revenue streams. Successful vaccine commercialization and platform validation open opportunities in underserved markets and future licensing deals.Read more
694
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
54users have followed this narrative
AN
US$13.78
26.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-35.05% p.a.
Profit Margin
18.72%
Future PE
48.8x
Price in 2029
US$16.95
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
Key Takeaways Heavy reliance on a limited vaccine portfolio and partners increases vulnerability to market saturation, operational risks, and diminishing revenue after short-term gains. Intensifying regulatory scrutiny and competition from larger players threaten margins, limit growth opportunities, and hinder Novavax's long-term profitability.Read more
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
68.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-53.99% p.a.
Profit Margin
16.25%
Future PE
72.61x
Price in 2028
US$7.32
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
Key Takeaways Strategic partnerships and innovative platforms are set to diversify revenue streams and enhance Novavax's long-term profitability across global vaccine markets. Accelerated demand for combination and next-generation vaccines, alongside increased government focus on preparedness, positions Novavax for durable growth and recurring high-margin income.Read more
89
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$25
59.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
-34.25% p.a.
Profit Margin
12.53%
Future PE
134.6x
Price in 2028
US$30.54
Trending Discussion
Recently Updated Narratives
AN
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Fair Value: US$13.78 26.6% undervalued intrinsic discount
54 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
Fair Value: US$6 68.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
Fair Value: US$25 59.6% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Novavax, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 2.70
- 64.77%
- 39.19%
- -191.2%
About NVAX
- Founded
- 1987
- Employees
- 749
- CEO
- WebsiteView website
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
